Related Experiment Videos
Ifosfamide in the treatment of ovarian cancer
1The Cleveland Clinic Cancer Center, The Cleveland Clinic Foundation, OH 44195, USA.
Seminars in Oncology
|June 1, 1996
Abstract:
Ifosfamide has been assessed in the treatment of ovarian cancer for more than two decades. The drug possesses well-documented but modest activity (10% to 15% range) in women with platinum/alkylating agent-resistant ovarian cancer. A potentially important ongoing clinical trial is attempting to define the level of activity of ifosfamide administered in the salvage setting to patients with advanced ovarian cancer who have been previously treated with a platinum drug plus paclitaxel but not an alkylating agent.